19981005
 Boston Scientific Pulls Its Nir-Sox Package After Finding Leaks   The Wall Street Journal,  Oct 6, 1998  The company said no patients have been harmed by the defect, but it decided to withdraw the Nir-Sox product as a "precautionary measure" after consulting with its scientific experts. The Nir with Sox accounted for about 60% of sales of its Nir stent, which was approved by the U.S. Food and Drug Administration in August, the company said. The Nir stent remains on sale without Sox.   
